‘PLANNING NEXT PHASE TRIALS GLOBALLY’

“2022 will be an important year for Cerecin. We have data readouts planned for our two ongoing Phase two pilot studies, in migraine prevention and infantile spasms. We plan to request pre-IND meetings with the US Food and Drug Administration for the investigation of tricaprilin in infantile spasms and tricaprilin in migraine. We are also planning our next phase trials in migraine, IS and Alzheimer’s disease that will be conducted globally. We plan to expand our investigational pipeline through our internal development efforts and pursuit of licensing opportunities. Finally, we plan to continue our fundraising efforts to progress the financial strategy that we have defined this year.”

- CHARLES STACEY, President and Chief Executive Officer, Cerecin, USA